Showing 6521-6530 of 7019 results for "".
- Wrinkle remover Revance files for $86 million IPOhttps://practicaldermatology.com/news/20140106-wrinkle_remover_revance_files_for_86_million_ipo/2459380/Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.
- NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indicationshttps://practicaldermatology.com/news/20140102-nexeption_llc_forms_new_company_alexar_therapeutics_inc_to_develop_novel_lxr_agonist_portfolio_for_dermatologic_indications/2459383/NeXeption, LLC, a biopharmaceutical management company that brings together product opportunities, management expertise and funding to reach compelling partnership milestones, has secured $21.5 million in Series A financing to form Alexar Therapeutic
- Cutera Appoints Scott Ashworth as Executive Vice President of Global Saleshttps://practicaldermatology.com/news/20131230-cutera_appoints_scott_ashworth_as_executive_vice_president_of_global_sales/2459385/Scott Ashworth recently joined Cutera as Executive Vice President of Global Sales. He brings twenty-five years of experience in building and leading global sales and marketing teams focused on commercialization of products, establishing distributio
- First Practice in Northwest Adopts ARTAS® Robotic Systemhttps://practicaldermatology.com/news/20131230-first_practice_is_northwest_adopts_artas_robotic_system/2459386/Advanced Hair Restoration of Bellevue, WA has installed the revolutionary ARTAS® Robotic System — the first and only FDA-cleared, physician-controlled, computer-assisted techno
- CSF 2013 Honors Top Resident Presentershttps://practicaldermatology.com/news/20131219-csf_2013_honors_top_resident_presenters/2459388/Nine residents have been recognized for their presentations at Cosmetic Surgery Forum 2013 held earlier this month. From a panel of residents who presented their research on a range of medical and cosmetic dermatology topics, the top
- Syneron's Home-Use Hair Removal Systems Receive Expanded Indicationhttps://practicaldermatology.com/news/20131219-synerons_home-use_hair_removal_systems_receive_expanded_indication/2459390/The FDA has granted Syneron Medical Ltd. and Iluminage Beauty an expanded indication for me™ brand of home-use hair removal systems. The systems, which utilize Syneron's proprietary elos technology, are now indicated for permanent reduction in hair growth. The me™ brand is owned and sold by Iluminag
- Cynosure Announces Successful Settlement of Patent Infringement Lawsuitshttps://practicaldermatology.com/news/20131217-cynosure_announces_successful_settlement_of_patent_infringement_lawsuits/2459393/Cynosure, Inc. will receive $10 million plus future royalty payments under a comprehensive settlement agreement with Tria Beauty, Inc. that ends the patent infringement litigation between Tria and Palomar Medical Technologies, which
- FDA Clears Scar Management Gel from Oculus and Quinnovahttps://practicaldermatology.com/news/20131204-fda_clears_scar_management_gel_from_oculus_and_quinnova/2459398/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for Microcyn Scar Management HydroGel, for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures, and trauma wounds. Oculus U.S. dermatology partner, Quinnova
- AAD Issues New Guidelines for Diagnosis and Assessment of Atopic Dermatitishttps://practicaldermatology.com/news/20131204-aad_issues_new_guidelines_for_diagnosis_and_assessment_of_atopic_dermatitis/2459399/The American Academy of Dermatology (AAD) recently announced the release of its new evidence-based guidelines for the diagnosis and assessment of atopic dermatitis based on an extensive review of the scientific literature on this chronic skin condition characterized by itchy, re
- FDA Approves Varithena to Treat Varicose Veinshttps://practicaldermatology.com/news/20131127-fda_approved_varithena_to_treat_varicose_veins/2459401/The FDA recently approved BTG plc's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. V